MMWR Morb Mortal Wkly Rep. 2013 Jan 25;62(3):56.
Buprenorphine (Subutex) and buprenorphine/naloxone (Suboxone) received Food and Drug Administration approval in 2002 for the treatment of opioid dependence. Introduction of these drugs expanded the availability of opioid-dependence treatment options to reduce the morbidity and mortality associated with opioid abuse, and buprenorphine has become an increasingly prescribed component of office-based treatment. However, unsupervised ingestion of buprenorphine-containing products by children is a growing concern.
丁丙诺啡（Subutex）和丁丙诺啡/纳洛酮（Suboxone）于 2002 年获得美国食品和药物管理局批准，用于治疗阿片类药物依赖。这些药物的引入扩大了阿片类药物依赖治疗选择的可及性，以降低与阿片类药物滥用相关的发病率和死亡率，丁丙诺啡已成为基于办公室的治疗中越来越常用的药物。然而，儿童未经监督摄入含丁丙诺啡的产品是一个日益令人关注的问题。
